HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reid, D. G. Articles by England, P. J. Search for Related Content PubMed PubMed Citation Articles by Reid, D. G. Articles by England, P. J. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 265, Issue 17, 9744-9753, 06, 1990

A proton nuclear magnetic resonance and molecular modeling study of calmidazolium (R24571) binding to calmodulin and skeletal muscle troponin C

DG Reid, LK MacLachlan, K Gajjar, M Voyle, RJ King and PJ England
Department of Physical Organic Chemistry, Smith Kline & French Research Ltd., Weiwyn, Herts, United Kingdom.

1H NMR spectroscopy at 360 MHz has been used to study the interactions between the calmodulin function inhibitor calmidazolium (R24571) and (i) calmodulin (CaM) and (ii) skeletal muscle troponin C (sTnC). One equivalent of racemic calmidazolium binds tightly to CaM and perturbs a number of protein signals, corresponding to residues in both dicalcium- binding domains, in a manner characteristic of slow exchange. Calmidazolium binds with lower affinity to sTnC but still induces widespread perturbations in both domains. Extensive spectral overlap precludes definite assignment of intermolecular nuclear Overhauser effect (NOEs) although intraprotein NOEs do indicate the nature of some drug-induced conformational changes. Relaxation enhancements induced by two spin-labeled calmidazolium analogues demonstrate that several methionine residues of CaM, significantly immobilized by calmidazolium binding, are in fact located at or near its binding sites. These and other residue-specific broadening effects have enabled low resolution models to be constructed of the predominantly hydrophobic drug-binding sites on each domain of CaM. The hydrophobic portions of calmidazolium itself, and its analogues, contact side chains of Ala-15, Leu-18, Phe- 19, Val-35, Met-36, Leu-37, Leu-39, Met-51, Met-71, Met-72, and Met-76 in the N-terminal domain of calmodulin, and Ala-88, Val-91, Phe-92, Val- 108, Met-109, Leu-112, Phe-141, and Met-145 in its C-terminal domain. The model, and an analogous one of sTnC, can be used to rationalize drug-induced changes in intraprotein NOEs. Issues pertaining to the possible simultaneous binding of calmidazolium to both globular domains of the proteins are discussed in terms of the experimental results and the overall structures of each protein.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Huo, G. Fu, X. Wang, W. K. W. Ko, and A. O. L. Wong Modulation of Calmodulin Gene Expression as a Novel Mechanism for Growth Hormone Feedback Control by Insulin-like Growth Factor in Grass Carp Pituitary Cells Endocrinology, September 1, 2005; 146(9): 3821 - 3835. [Abstract] [Full Text] [PDF]

				L. S. Wright, P. J. Bertics, and F. L. Siegel Calmodulin N-Methyltransferase. KINETICS, MECHANISM, AND INHIBITORS J. Biol. Chem., May 31, 1996; 271(22): 12737 - 12743. [Abstract] [Full Text] [PDF]

				X. Lin, D. G. Dotson, and J. A. Putkey Covalent Binding of Peptides to the N-terminal Hydrophobic Region of Cardiac Troponin C Has Limited Effects on Function J. Biol. Chem., January 5, 1996; 271(1): 244 - 249. [Abstract] [Full Text] [PDF]